

High-Risk CASE STUDY Mr X

DetermaRx™ is a treatment stratification test to identify patients with stage I and IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.¹

Presentation

81-Year Old Male

presented with right lower lobe pneumonia in 09/2019; patient was placed on an antibiotic but did not improve

Medical History

CT scan revealed 2.3 cm lesion in the left lung, CT-guided biopsy of LUL nodule: moderately differentiated adenocarcinoma; CK7+, CK20-, TTF-1+, Past Medical History: Hypertension, hyperlipidemia, mild psoriasis


Medications

Enalapril, Pravastatin

Social History

25 PY, quit 40 years ago

Diagnosis



Workup

Surgery

01/2020

Wedge resection of LUL and mediastinoscopy

Pathology

Size: 2.8 x 2.1 x 1.8 cm


Mediastinoscopy: negative LNs

Histology: adenocarcinoma, invasive

Margins: negative

T1cN0M0 (Stage IA3)

DetermaRx Results



Follow-up

Plan

Initiated on carboplatin-based doublet and pemetrexed

Patient

Completed 4 cycles without any clinical deterioration or complications

Status

Currently doing well, undergoing surveillance for next five years

No Recurrence



Conclusion

Approximately 30% of patients with Stage IA disease have high-risk biology.² This patient was given chemotherapy based on his high-risk DetermaRx result and tolerated the adjuvant treatment well.

This case study was provided courtesy of Dr. Edgardo Santos, Florida Precision Oncology.

REFERENCES 1. Woodard GA, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. *Clinical Lung Cancer* 19:58-64. 2. Howlader, et al. (2018) Differences in breast cancer survival by molecular subtypes in the United States. *Cancer Epidemiol Biomarkers Prev* 27:619.